Department of Psychiatry and Behavioral Sciences, University of California, Davis, California, USA.
Am J Addict. 2010 Mar-Apr;19(2):155-68. doi: 10.1111/j.1521-0391.2009.00014.x.
Paranoia in methamphetamine (MA) users is not well characterized or understood. To investigate this phenomenon, we created the Methamphetamine Experience Questionnaire (MEQ), and tested its reliability and validity in assessing MA-induced paranoia. We administered the MEQ to 274 MA-dependent subjects. Of the total subjects, 45% (123) first experienced paranoia with MA use; 55% did not. Obtaining or using a weapon while paranoid was common (37% and 11% of subjects with MA-induced paranoia, respectively). Test-retest and inter-rater reliability for MA-induced paranoia showed substantial agreement (kappa = .77, p < .05 and kappa = .80, p < .05, respectively). First episodes of paranoia occurred more often with intravenous use of MA, and subsequent episodes at higher doses. There was modest correlation between paranoia on the MEQ and the Brief Symptom Inventory (BSI) paranoid ideation scale (rho = .27, p < .05). As expected, there was a poor correlation between paranoia on the MEQ and the BSI depression scale (rho = .14, p = .07). The MEQ provides useful information on drug use variables that contribute to paranoia commonly associated with MA use. (Am J Addict 2010;00:1-14).
methamphetamine（MA）使用者的妄想症尚未得到充分的描述和理解。为了研究这一现象，我们创建了 methamphetamine 体验问卷（MEQ），并测试了其评估 MA 诱导的妄想症的可靠性和有效性。我们对 274 名 MA 依赖者进行了 MEQ 测试。在所有受试者中，45%（123 人）首次在使用 MA 时出现妄想症；55%的人没有。在妄想时获得或使用武器是很常见的（分别有 37%和 11%的 MA 诱导的妄想症患者）。MA 诱导的妄想症的测试重测和评分者间可靠性显示出实质性的一致性（kappa =.77，p <.05 和 kappa =.80，p <.05）。妄想症的首次发作更常发生在 MA 的静脉使用中，随后的发作则发生在更高的剂量。MEQ 上的妄想与 Brief Symptom Inventory（BSI）偏执观念量表之间存在适度的相关性（rho =.27，p <.05）。正如预期的那样，MEQ 上的妄想与 BSI 抑郁量表之间的相关性较差（rho =.14，p =.07）。MEQ 提供了与 MA 使用相关的妄想症的药物使用变量的有用信息。（美国成瘾杂志 2010；00：1-14）。
